Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Mr Metals who wrote (31675)	12/9/1998 4:40:00 PM
From: HARLEYFATBOY	Read Replies (1) \| Respond to of 34592

Flurry of Cancer Coups Follows Major Conference Business Wire - December 09, 1998 12:12 SEATTLE--(BUSINESS WIRE)--Dec. 9, 1998--While Christmas shoppers troop to the mall, biotechnology researchers trek to year-end conferences to report the latest efforts of their companies to combat major diseases. We're waiting for numbers on retailers' success, but the data are back from biotech: it's been a banner year. "Industry conferences are integral to the inner workings of the drug-development process," explained Tim Quast of Informed Investors Forum in Sacramento, Calif., which hosts the Cancer Forum in Seattle Dec. 12 (See www.informedinvestors.com for details). "They are rallying points," Quast added, "for all the parties involved in the process -- scientists, research facilities, biotechnology and pharmaceutical executives and investors -- where everyone can compare notes, reinforce the validity of their efforts and offer glimpses into major advances. It's always exciting." The American Society of Hematology (ASH) held its 40th annual conference this week in Miami, and an outbreak of major announcements has followed. Massachusetts General Hospital (MGH) and BioTransplant (Nasdaq: BTRN) reported positive results on a new therapy for treating blood cell cancers that re-programs the immune system and replaces cancerous blood cells. Aastrom Biosciences (Nasdaq:ASTM) said its researchers were successfully growing sufficient numbers of umbilical cord blood cells as a promising source of replacement cells in bone marrow transplants. Also, research funded by Genentech (NYSE:GNE) and Pharmacia & Upjohn (NYSE:PNU) showed that a genetically engineered drug stimulated stem cells -- the body's primitive bone marrow cells and the ultimate source of all blood cells -- to migrate out of the bone marrow and into the bloodstream, thus preserving a source of stem cells during chemotherapy, which kills both healthy and cancerous cells. Seattle's own Fred Hutchinson Cancer Research Center (FHCRC) presented data at ASH on a potential new treatment for cancer that could make the indiscriminate cell destruction caused by chemotherapy a thing of the past. The research effort connects an antibody to chemotherapy molecules to specifically target cancerous cells. Dr. Leland Hartwell, Director of the FHCRC, keynotes the only conference for individual investors focused on cancer, the Seattle Cancer Forum on Dec. 12 at the Downtown Hilton. For details call Informed Investors Forum at 800/992-4683.